Rosetta Stone (RST) Share Price Rose While Osmium Partners Has Decreased Holding; Acorda Therapeutics (ACOR) Holder Baker Bros Advisors LP Decreased Its Stake

April 17, 2018 - By Peter Erickson

Acorda Therapeutics, Inc. (NASDAQ:ACOR) Logo

Julian Baker decreased its stake in Acorda Therapeutics Inc. (ACOR) by 60.35% based on its latest 2017Q4 regulatory filing with the SEC. Baker Bros Advisors Lp sold 313,534 shares as the company’s stock rose 9.26% while stock markets declined. The hedge fund run by Julian Baker held 205,966 shares of the health care company at the end of 2017Q4, valued at $4.42M, down from 519,500 at the end of the previous reported quarter. Baker Bros Advisors Lp who had been investing in Acorda Therapeutics Inc. for a number of months, seems to be less bullish one the $1.10 billion market cap company. The stock increased 0.43% or $0.1 during the last trading session, reaching $23.45. About 18,664 shares traded. Acorda Therapeutics, Inc. (NASDAQ:ACOR) has declined 10.61% since April 17, 2017 and is downtrending. It has underperformed by 22.16% the S&P500.

John H Lewis decreased its stake in Rosetta Stone Inc (RST) by 9.48% based on its latest 2017Q4 regulatory filing with the SEC. Osmium Partners Llc sold 208,017 shares as the company’s stock rose 4.66% while stock markets declined. The hedge fund run by John H Lewis held 1.99M shares of the prepackaged software company at the end of 2017Q4, valued at $24.76 million, down from 2.19 million at the end of the previous reported quarter. Osmium Partners Llc who had been investing in Rosetta Stone Inc for a number of months, seems to be less bullish one the $302.04M market cap company. The stock increased 1.05% or $0.14 during the last trading session, reaching $13.44. About 2,923 shares traded. Rosetta Stone Inc. (NYSE:RST) has risen 36.60% since April 17, 2017 and is uptrending. It has outperformed by 25.05% the S&P500.

Baker Bros Advisors Lp, which manages about $8.20 billion and $11.54 billion US Long portfolio, upped its stake in Ignyta Inc. (NASDAQ:RXDX) by 85,067 shares to 1.38 million shares, valued at $36.96M in 2017Q4, according to the filing. It also increased its holding in Ascendis Pharma A/S by 269,978 shares in the quarter, for a total of 2.62M shares, and has risen its stake in Gw Pharmaceuticals Plc (NASDAQ:GWPH).

Analysts await Acorda Therapeutics, Inc. (NASDAQ:ACOR) to report earnings on May, 2 before the open. They expect $0.33 earnings per share, up 180.49% or $0.74 from last year’s $-0.41 per share. ACOR’s profit will be $15.48M for 17.77 P/E if the $0.33 EPS becomes a reality. After $0.45 actual earnings per share reported by Acorda Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -26.67% negative EPS growth.

Since January 18, 2018, it had 0 buys, and 2 insider sales for $1.81 million activity. Wasman Jane sold 34,520 shares worth $952,319.

Among 14 analysts covering Acorda Therapeutics (NASDAQ:ACOR), 5 have Buy rating, 1 Sell and 8 Hold. Therefore 36% are positive. Acorda Therapeutics had 45 analyst reports since August 25, 2015 according to SRatingsIntel. As per Tuesday, August 25, the company rating was maintained by Cowen & Co. Jefferies maintained it with “Hold” rating and $25.0 target in Wednesday, November 15 report. On Monday, June 5 the stock rating was maintained by Cowen & Co with “Buy”. The rating was upgraded by Goldman Sachs to “Neutral” on Wednesday, February 15. The firm has “Neutral” rating by Goldman Sachs given on Wednesday, March 30. The firm has “Hold” rating given on Wednesday, November 15 by Cantor Fitzgerald. As per Tuesday, August 29, the company rating was maintained by Cowen & Co. On Tuesday, August 25 the stock rating was maintained by JP Morgan with “Neutral”. The stock of Acorda Therapeutics, Inc. (NASDAQ:ACOR) has “Hold” rating given on Tuesday, June 6 by J.P. Morgan. Stifel Nicolaus maintained the stock with “Buy” rating in Tuesday, October 31 report.

Investors sentiment decreased to 0.99 in Q4 2017. Its down 0.23, from 1.22 in 2017Q3. It dived, as 24 investors sold ACOR shares while 46 reduced holdings. 23 funds opened positions while 46 raised stakes. 48.17 million shares or 6.13% less from 51.31 million shares in 2017Q3 were reported. Dimensional Fund Advsrs Lp has 0.03% invested in Acorda Therapeutics, Inc. (NASDAQ:ACOR) for 2.95 million shares. Baker Bros Limited Partnership owns 205,966 shares. Kbc Gp Nv reported 64,007 shares or 0.01% of all its holdings. 14 were accumulated by Assetmark. Teachers Retirement Sys Of The State Of Kentucky invested in 0% or 11,700 shares. Massachusetts Finance Svcs Company Ma holds 0% of its portfolio in Acorda Therapeutics, Inc. (NASDAQ:ACOR) for 48,429 shares. State Teachers Retirement owns 0% invested in Acorda Therapeutics, Inc. (NASDAQ:ACOR) for 59,236 shares. Great West Life Assurance Can invested in 0% or 60,160 shares. The New York-based Metropolitan Life Insurance Com New York has invested 0% in Acorda Therapeutics, Inc. (NASDAQ:ACOR). State Board Of Administration Of Florida Retirement Systems has invested 0% in Acorda Therapeutics, Inc. (NASDAQ:ACOR). Pub Sector Pension Inv Board stated it has 0.01% in Acorda Therapeutics, Inc. (NASDAQ:ACOR). Bogle Invest Limited Partnership De holds 249,431 shares or 0.39% of its portfolio. Prudential Fincl invested in 0.01% or 240,388 shares. Alps Advsrs Inc owns 51,801 shares or 0.01% of their US portfolio. Prelude Cap Mgmt Ltd has invested 0.01% of its portfolio in Acorda Therapeutics, Inc. (NASDAQ:ACOR).

Among 3 analysts covering Rosetta Stone (NYSE:RST), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Rosetta Stone had 5 analyst reports since August 11, 2015 according to SRatingsIntel. The firm has “Hold” rating by Zacks given on Tuesday, August 11. The company was upgraded on Thursday, October 20 by Barrington Research. The stock has “Buy” rating by Barrington on Wednesday, March 14.

Investors sentiment increased to 1.61 in 2017 Q4. Its up 0.35, from 1.26 in 2017Q3. It improved, as 10 investors sold RST shares while 21 reduced holdings. 20 funds opened positions while 30 raised stakes. 15.17 million shares or 1.48% less from 15.40 million shares in 2017Q3 were reported. Acadian Asset Mgmt Lc stated it has 364,900 shares or 0.02% of all its holdings. Prelude Cap Mgmt Ltd has invested 0% in Rosetta Stone Inc. (NYSE:RST). National Bank Of Montreal Can has invested 0% of its portfolio in Rosetta Stone Inc. (NYSE:RST). Jpmorgan Chase And Commerce reported 116,407 shares. Manufacturers Life The has 14,472 shares. Parallax Volatility Advisers LP invested 0% of its portfolio in Rosetta Stone Inc. (NYSE:RST). Spark Management Ltd Liability Co holds 84,600 shares or 0.06% of its portfolio. Tiaa Cref Invest Mngmt Ltd Liability reported 0% stake. Ariel Invests Lc invested 0.43% in Rosetta Stone Inc. (NYSE:RST). Rbf Capital Limited Co has 0.08% invested in Rosetta Stone Inc. (NYSE:RST) for 58,864 shares. Schwab Charles Mngmt Inc owns 0% invested in Rosetta Stone Inc. (NYSE:RST) for 59,068 shares. Bancorp Of Mellon holds 0% or 62,161 shares in its portfolio. Oberweis Asset Management Incorporated has 89,400 shares. Martingale Asset Management Limited Partnership has 114,051 shares for 0.02% of their portfolio. State Board Of Administration Of Florida Retirement stated it has 13,738 shares or 0% of all its holdings.

Analysts await Rosetta Stone Inc. (NYSE:RST) to report earnings on May, 8. They expect $-0.39 earnings per share, down 1,075.00% or $0.43 from last year’s $0.04 per share. After $-0.14 actual earnings per share reported by Rosetta Stone Inc. for the previous quarter, Wall Street now forecasts 178.57% negative EPS growth.

Rosetta Stone Inc. (NYSE:RST) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts